Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06189170
EARLY_PHASE1
Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients
Sponsor: Kariya Pharmaceuticals
View on ClinicalTrials.gov
Summary
This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of KP405 as a potential new treatment for Parkinson's disease.
Official title: A Phase I, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate KP405. Part 1: Single Ascending Dosing in Healthy Participants. Part 2: Multiple Ascending Dosing in Healthy Participants and Parkinson's Disease Patients.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
88
Start Date
2024-08-01
Completion Date
2026-03-31
Last Updated
2025-03-07
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
KP405
Experimental drug
DRUG
Placebo
Placebo
Locations (1)
MAC
Manchester, United Kingdom